phox subunit is an essential protein in the activation of NAD(P)H oxidase. Here we report the preliminary characterisation of the human p22 phox gene promoter. The p22 phox promoter contains TATA and CCAC boxes and Sp1, Q Q-interferon and nuclear factor U UB sites. We screened for mutations in the p22 phox promoter and identi¢ed a new polymorphism, localised at position 3 3930 from the ATG codon, which was associated with hypertension. Mutagenesis experiments showed that the G allele had higher promoter activity than the A allele. These results suggest that the 3 3930 A=G polymorphism in the p22 phox promoter may be a novel genetic marker associated with hypertension.
Introduction

NAD(P)H oxidase is the major inducible source of superoxide anion ( c O
2 ) in phagocytes. In these cells, this enzyme has a bactericidal function and generates c O 3 2 upon stimulation by pathogens [1] . This oxidase is a membrane-bound enzyme that catalyses a single electron reduction of molecular oxygen to form c O 3 2 . It consists of a membrane-associated cytochrome b 558 , two cytosolic components p47 phox and p67 phox , and the small GTPase protein rac2 [2, 3] . Cytochrome b 558 , which is the ¢nal electron transporter from NAD(P)H to molecular oxygen, consists of a large and a small subunit, gp91 phox and p22 phox respectively [4] . The NAD(P)H oxidase system is also considered to be the most important source of c O 3 2 in vascular cells such as smooth muscle cells (VSMCs) and endothelial cells [5^7] . Despite the similarities between vascular and phagocytic NAD(P)H oxidases, it has been suggested that vascular oxidase represents a novel family of enzymes [8] .
Oxidative stress induced by c O 3 2 has been implicated in the development of hypertension [9, 10] . A major component of NAD(P)H oxidase is the p22 phox protein, a critical subunit that plays an essential role in NAD(P)H oxidase-dependent c O 3 2 generation in vascular cells [11] . Enhanced vascular NAD(P)H oxidase-driven c O 3 2 production is associated with upregulation of p22 phox mRNA in several models of hypertension, including the spontaneously hypertensive rat (SHR) [12, 13] .
The gene encoding human p22 phox (CYBA) is located on chromosome 16q24 and has several allelic variants [14^17]. Recently we reported the existence of ¢ve functional polymorphisms in the promoter of the p22 phox gene in SHR, associated with higher transcriptional activity [18] . Thus, the ¢rst goal of this study was to perform the structural and functional characterisation of the human p22 phox gene, with the ¢nal purpose of screening for new polymorphisms in its promoter region.
Materials and methods
Subjects
The study population consisted of Caucasian subjects who were referred to our institution for routine medical examination. The case group of hypertensives consisted of 88 subjects with elevated systolic blood pressure (SBP s 139 mm Hg) and/or elevated diastolic blood pressure (DBP s 89 mm Hg). As a control group, 68 normotensive subjects were also studied. Subjects agreed to participate in the study, which was carried out in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethical Committee of the University Clinic of Navarra.
Isolation of the p22
phox gene 5P extreme A human gene library constructed in vector P1 was screened by conventional methods, and a positive clone was obtained. A fragment of approximately 5 kb, obtained by digestion with SacI, was cloned in plasmid pUC19, thus obtaining clone p5S. Sequencing of clone p5S was performed using primers of vector pUC19 and internal primers from the cloned fragment. Sequencing reactions were carried out in both strands using the Autoread sequencing kit (Amersham).
Primer extension
Primer extension was carried out using a dye-labelled antisense oligonucleotide (5P-ACATGGCCCACTCGATCT-3P) located at positions +8 to +25 relative to the ATG codon. The oligonucleotide was hybridised with 1 Wg human kidney poly(A) þ RNA (Clontech) and extended using Superscript II reverse transcriptase (Gibco BRL). The products of this reaction were analysed by electrophoresis on a 6% polyacrylamide denaturing gel on the ALF1 DNA Analysis System (Amersham) and the sizes of the products were determined by comparison with a DNA sequence obtained with the oligonucleotide used.
Plasmid construction
Digestion of clone p5S with SacI and Sau3AI released a fragment of V1200 bp containing the whole promoter and the codon ATG of the p22 phox gene. This fragment was then subcloned in 5P position in relation to the luciferase gene, in the SacI/BglII-digested pGL3basic plasmid. We thus obtained the construct c1. Deleted constructs were obtained by double digestion of c1, using SacI in the plus 5P end of the promoter and di¡erent endonucleases (BalI, SmaI and ApaI) in the plus 3P end of the promoter. The restriction ends were ¢lled using the DNA polymerase I Klenow fragment, and the blunt edges were ligated for subsequent transformation. As a result of this approach, constructs c2, c3 and c4 were obtained. For the in vitro mutagenesis experiments we employed construct c1, which contains the G allele at the 3930 polymorphic site, as a template. The mutated construct, in which the G allele at the 3930 polymorphic site in the p22 phox promoter was replaced by the A allele, was obtained using the QuikChange Site-Directed Mutagenesis kit (Stratagene) with the primers 5P-GGGGAATAAACCAGCATTACTGCCTCCGGCCTC-CG-3P and 5P-CGGAGGCCGGAGGCAGTAATGCTGGTTTATT-CCCC-3P. Correct orientation and sequence of the p22 phox promoter in all constructs were con¢rmed by restriction enzyme analysis, polymerase chain reaction (PCR), and DNA sequencing.
Cell culture, transfection experiments and luciferase activity
Primary VSMCs were obtained from thoracic aorta of 30-week-old SHR as previously reported [19] . The rat aortic smooth muscle cell line A7r5 was cultured in Dulbecco's modi¢ed Eagle's medium with 10% foetal calf serum supplemented with sodium pyruvate. A7r5 or VSMCs were transfected as previously reported [19] and the assays for luciferase activity were performed using Dual-Luciferase Reporter Assay System (Promega). The ratio of ¢re£y luciferase level to Renilla luciferase level was used as a measurement of p22 phox promoter activity.
Identi¢cation of polymorphisms in the p22
phox promoter To screen for mutations in the p22 phox promoter, genomic DNA was extracted from blood and a 1167-bp fragment containing the whole promoter was ampli¢ed by PCR using the primers 5P-CAGG-GAAGGGTCACTGTG-3P and 5P-ACATGGCCCACTCGATCT-3P. The PCR products were sequenced directly using a Thermo Sequenase kit (Amersham) after column puri¢cation.
Genotyping
Since the A-to-G mutation of the 3930 A=G polymorphism introduces a BbvI digestion site, restriction fragment length polymorphism (RFLP) was used to analyse this polymorphism in all subjects. A 650-bp fragment containing the 3930 site was ampli¢ed employing the oligonucleotides F 1 (5P-GGAAACCACCAAGTGCCTCGGATGG-3P) and R 1 (5P-TCTGCACCCTGCTACCAAGGAC-3P). Digestion of the PCR product by BbvI yields 504-, 85-, 57-and 15-bp fragments in the G allele, whereas BbvI makes 589-, 57-and 15-bp fragments in the A allele. Genotypes were scored according to the patterns of DNA bands, and the results were con¢rmed by duplicate analysis. To be sure of the accuracy of the method, a subset of 650-bp fragments were sequenced.
Statistical analysis
Data are expressed as mean þ S.E.M. M 2 analysis was used to test for deviation of genotype distribution from Hardy^Weinberg equilibrium and to determine whether there were any signi¢cant di¡erences in allele or genotype frequencies between cases and controls. Statistical signi¢cance in the luciferase activity experiments among constructs and in the clinical data among genotypes was assessed by ANOVA followed by Sche¡e ¤ post-hoc test. Di¡erences in the luciferase activity experiments between allelic variants were assessed by Student's t-test. A P value 6 0.05 was considered statistically signi¢cant.
Results
Structure of the p22
phox gene 5P extreme Sequence analysis of clone p5S corroborated the presence of the ¢rst four exons and three introns, which are £anked by typical splice donor and acceptor dinucleotides, with an identical sequence to the previously reported human p22 phox gene exon^intron organisation [14] . In addition, we identi¢ed 1173 bp located upstream of the ATG codon corresponding to the promoter region. Computer analysis of this sequence showed the presence of a TATA box and a CCAC box. Other potential binding sites for GAGA elements, Q-interferon and nuclear factor UB (NF-UB) that might transcriptionally regulate p22 phox gene expression were also identi¢ed (Fig. 1) . It is interesting to note the presence of multiple binding sites for the SP1 transcription factor close to the ATG codon. A primer extension experiment pointed to a C located 231 nucleotides upstream of the codon ATG as the predominant site for transcription initiation (Fig. 1). 
Promoter activity of the p22
phox gene In order to establish if the potential promoter region was functional, a fragment of 1185 bp containing the whole promoter was subcloned in a plasmid carrying the luciferase gene (c1 clone) ( Fig. 2A) and transfected in A7r5 cells. Fig. 2B shows a substantial promoter activity of construct c1 in A7r5 cells. To characterise more precisely the regions required to control promoter activity, we cloned a series of DNA fragments of the p22 phox promoter obtained by progressive dele- tion of the c1 clone ( Fig. 2A) . The resulting plasmids were transfected in A7r5 cells. As shown in Fig. 2B , constructs c2 and c3 generated signals similar to those obtained with construct c1. However, the promoter activity of construct c4 showed a signi¢cant decrease (P 6 0.05).
Identi¢cation of a new polymorphism in the human p22
phox promoter To search for polymorphisms in the 5P £anking region of the human p22 phox gene, a 1167-bp fragment corresponding to the p22 phox promoter was ampli¢ed from genomic DNA from 20 patients with essential hypertension and sequenced as described above. Computer analysis of the p22 phox promoter sequences revealed the existence of A-to-G substitution at 3930 from the ATG codon (Fig. 1) .
Association of the 3930
A=G polymorphism of the p22 phox gene with essential hypertension The clinical characteristics of subjects classi¢ed according to blood pressure values are shown in Table 1 . A total of 88 hypertensives and 68 normotensives were genotyped for the 3930 A=G polymorphism by RFLP (Fig. 3) . Distributions of genotypes and alleles from both groups are presented in Table  2 . Genotype frequencies were consistent with the HardyŴ einberg equilibrium law. Frequencies of genotypes for the 3930 A=G polymorphism in hypertensive patients di¡ered signi¢cantly from those in normotensive subjects (M 2 = 6.4, P 6 0.02). No signi¢cant di¡erences were found in the clinical characteristics of hypertensives classi¢ed according to 3930 A=G polymorphism genotypes (Table 3) .
Functional e¡ect of the 3930
A=G polymorphism of the p22 phox gene To investigate whether the G-to-A substitution had an effect on gene expression, transfection experiments on VSMCs obtained from SHR rats with each allelic promoter^reporter gene construct were carried out. The G allele exhibited higher luciferase activity than the A allele in SHR cells. As shown in Fig. 4 , reporter gene expression driven by the G allelic p22 phox promoter was 30% higher (P 6 0.05) than reporter gene expression directed by the A allelic promoter.
Discussion
In the present study we have characterised the promoter region of the human p22 phox gene for the ¢rst time. The human p22 phox promoter possesses a typical TATA and a CCAC box and several potential consensus sequences for transcriptional factors, such as GAGA elements, Q-interferon and NF-UB. Furthermore, we have identi¢ed several SP1 binding sites in close proximity to the ATG codon that can also play a signi¢cant role in p22 phox promoter activity. The construct c1, which contained 1173 bp upstream and 12 bp downstream of the ATG codon, was used for luciferase reporter gene assays. In this regard, a substantial promoter activity of construct c1 proved the functionality of this promoter. However, we observed a signi¢cant decrease in the promoter activity of construct c4. Deletion analysis of the promoter region revealed that TATA and CCAC boxes and several putative binding sites such as Elk1, GAGA and NF-UB, situated between positions 3201 and 3429, may be important for the basic promoter activity.
The main ¢nding of the current study is the identi¢cation of a new polymorphism within the p22 phox gene promoter, located at position 3930 from the ATG codon. Genotyping studies of this polymorphism in cases and controls showed a signi¢cant increase in G allele frequency in hypertensives. Our group has recently reported the presence of functional polymorphisms in the p22 phox promoter that resulted in a higher transcriptional activity of the p22 phox gene in SHR [18] . In the same study we showed that VSMCs obtained from the aorta of SHR exhibit a characteristic hypertensive phenotype. Thus, these cells represent a good in vitro model for the study of the e¡ects of hypertensive stimuli on the allelic variants of the 3930 A=G polymorphism and hence on the promoter activity. In this regard, our ¢ndings showing a higher reporter gene expression driven by the G allelic p22 phox promoter than that of the A allelic promoter in SHR VSMCs would suggest that this polymorphism is functionally relevant. In a multifactorial chronic disease such as hypertension, a p22 phox transcriptional activity 30% higher for the G allele than for the A allele could be expected to play a signi¢cant role in this trait. Thus, these observations suggest that the 3930 A=G polymorphism may be involved in the control of the expression of the p22 phox gene under hypertensive conditions, although new studies are necessary to address the in£uence of genotypes on p22 phox mRNA expression.
Recent ¢ndings have claimed the potential relevance of p22 phox gene overexpression in hypertension [20] . An increased p22 phox mRNA expression leading to a greater NAD(P)H oxidase-driven c O 3 2 production has been reported in SHR with diminished nitric oxide availability and endothelial dysfunction [12] . On the other hand, we have shown that p22 phox polymorphisms are able to regulate p22 phox expression and consequently NAD(P)H oxidase activity in SHR [18] . It is, thus, tempting to speculate that the polymorphism of the p22 phox gene reported here may upregulate the expression and activity of NAD(P)H oxidase in hypertension. Although further functional studies are required to test this hypothesis, its signi¢cance is underlined by clinical data, indicating the occurrence of increased c O 3 2 production in hypertensives [21, 22] . Nevertheless, we cannot discard the possibility that 3930 A=G polymorphism could be in linkage disequilibrium with another functional polymorphism.
In summary, we have characterised the genomic structure of the human p22 phox gene promoter. In addition, we have identi¢ed the 3930 A=G polymorphism in the p22 phox promoter that appears to be a novel genetic marker associated with hypertension. Since this is a pilot study, it is necessary to con¢rm these preliminary results in further studies. Nevertheless, our ¢ndings show that expression of the p22 phox mRNA in hypertension depends on the presence on the G or A allele for this polymorphic site.
